Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (7): 74-82.doi: 10.6040/j.issn.1671-7554.0.2022.0238

Previous Articles     Next Articles

A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer

QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen   

  1. Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2022-07-27

PDF (PC)

91

Abstract: Objective A network meta-analysis was performed to compare the efficacy and safety of first-line treatment regimens of advanced driver-gene wild-type and programmed death-ligand 1(PD-L1)negative non-squamous non-small cell lung cancer(NSCLC). Methods First-line treatment trials of advanced driver-gene wild-type non-squamous NSCLC were searched in PubMed, Cochrane Library, Embase database and ClinicalTrials.gov website. Randomized controlled trials(RCTs)comparing first-line treatment regimens including chemotherapy, immune checkpoint inhibitors(ICIs), antiangiogenic therapy and their combinations were included. StataMP 16.0 and R 4.1.0 were used for data analysis. Results A total of 10 RCTs were included, involving 5,731 patients and 10 treatment regimens. There was no statistically significant difference in overall survival(OS)and progression-free survival(PFS)among the treatment regimens(P>0.05). The regimen of pembrolizumab + chemotherapy had the longest OS, and the regimen of nivolumab+bevacizumab+chemotherapy had the longest PFS. The objective response rates(ORR)of atezolizumab+ chemotherapy and pembrolizumab+chemotherapy were higher than that of chemotherapy(OR=1.66, 95%CI: 1.07-2.59; OR=2.68, 95%CI: 1.40-5.11). In terms of allgrade adverse events(AEs), camrelizumab + chemotherapy was higher(AEs)than chemotherapy and sintilimab + chemotherapy(OR=1.05, 95%CI: 1.01-1.08; OR=1.05, 95%CI: 1.01-1.09). In terms of ≥3 grade AEs, there was no statistically significant difference among the treatment regimens(P>0.05). Conclusion For patients with advanced driver-gene wild-type PD-L1 negative non-squamous NSCLC, there was no significant difference in survival benefits among the existing first-line treatment regimens. The combination of immunotherapy and chemotherapy was more effective, but the adverse events were also more significant. A reasonable treatment regimen should be selected according to the individual conditions.

Key words: Non-small cell lung cancer, Network meta-analysis, Programmed death-ligand 1, Chemotherapy, Antiangiogenic therapy, Immunotherapy

CLC Number: 

  • R734.2
[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[2] 黄岩, 张力. 2020 CSCO非小细胞肺癌诊疗指南更新要点解读[J]. 临床内科杂志, 2020, 37(8): 603-605.
[3] 王建丽, 王筱静, 孙玉莲, 等. 吉非替尼联合化疗治疗50例晚期非小细胞肺癌患者的疗效[J]. 山东大学学报(医学版), 2019, 57(11): 20-26. WANG Jianli, WANG Xiaojing, SUN Yulian, et al. Clinical effect of gefitinib combined with chemotherapy on patients with advanced non-small cell lung cancer [J]. Journal of Shandong University(Health Sciences), 2019, 57(11): 20-26.
[4] Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer [J]. J Hematol Oncol, 2020, 13(1): 58. doi: 10.1186/s13045-020-00881-7.
[5] Herbst R, Jassem J, Abogunrin S, et al. A network meta-analysis of cancer immunotherapies versus chemotherapy for first-line treatment of patients with non-small cell lung cancer and high programmed death-ligand 1 expression [J]. Front Oncol, 2021, 11: 676732. doi: 10.3389/fonc.2021.676732. eCollection 2021.
[6] Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021 [J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[7] Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer(CameL): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet Resp Med, 2021, 9(3): 305-314.
[8] Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study(Oncology pRogram by InnovENT anti-PD-1-11)[J]. J Thorac Oncol, 2020, 15(10): 1636-1646.
[9] West H, Mccleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer(IMpower130): a multicentre, randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2019, 20(7): 924-937.
[10] Nishio M, Barlesi F, West H, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 Trial [J]. J Thorac Oncol, 2021, 16(4): 653-664.
[11] Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC [J]. J Thorac Oncol, 2021, 16(11): 1909-1924.
[12] Borghaei H, Langer CJ, Gadgeel S, et al. 24-month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for-advanced nonsquamous non-small cell lung cancer [J]. J Thorac Oncol, 2019, 14(1): 124-129.
[13] Garon EB, Aerts J, Kim JS, et al. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: a post hoc analysis of KEYNOTE-189 [J]. Lung Cancer, 2021, 155: 53-60. doi: 10.1016/j.lungcan.2021.02.021.
[14] Hellmann MD, Paz-ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer [J]. New Engl J Med, 2019, 381(21): 2020-2031.
[15] Lu S, Wang J, Yu Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC(RATIONALE 304): a randomized phase 3 trial [J]. J Thorac Oncol, 2021, 16(9): 1512-1522.
[16] Sugawara S, Lee JS, Kang JH, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer [J]. Ann Oncol, 2021, 32(9): 1137-1147.
[17] Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review [J]. JAMA, 2019, 322(8): 764-774.
[18] Gubens MA, Davies M. NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer [J]. J Natl Compr Canc Netw, 2019, 17(5.5): 574-578.
[19] Shi Y, Duan J, Guan Q, et al. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: a meta-analysis of 4939 patients from randomized controlled trials [J]. Int Immunopharmacol, 2020, 84: 106452. doi:10.1016/j.intimp.2020.106452.
[20] Liu J, Li C, Seery S, et al. Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis [J]. Oncoimmunology, 2020, 9(1): 1746112. doi: 10.1080/2162402X.2020.1746112.
[21] 秦叔逵, 马军, 李进, 等. 卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识[J]. 临床肿瘤学杂志, 2020, 25(9): 840-848. QIN Shukui, MA Jun, LI Jin, et al. Expert consensus on the clinical diagnosis and treatment of camrelizumab induced reactive cutaneous capillary endothelial proliferation [J]. Chinese Clinical Oncology, 2020, 25(9): 840-848.
[22] Gadgeel S, Rodríguez-abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer [J]. J Clin Oncol, 2020, 38(14): 1505-1517.
[23] Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab(Avastin®)in cancer treatment: a review of 15 years of clinical experience and future outlook [J]. Cancer Treat Rev, 2020, 86: 102017. doi: 10.1016/j.ctrv.2020.102017.
[24] Shroff GS, Strange CD, Altan M, et al. Post-immunotherapy imaging in lung cancer [J]. Clin Radiol, 2022, 77(1): 44-57.
[25] Hellmann MD, Paz-ares L, Bernabe CR, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer [J]. N Engl J Med, 2019, 381(21): 2020-2031.
[1] Xiangyan RUAN,Jiaojiao CHENG,Juan DU,Muqing GU. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[2] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[3] GAO Huijiang, WEI Yucheng. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27.
[4] LIU Huining, PENG Jun, REN Yingchun, YANG Guang, WANG Wenhao, LIU Jinfeng, TIAN Qing. Comparison of 34 cases of thoracoscopic wedge resection and 21 cases of segmental resection for stage ⅠA1 non-small cell lung cancer in area P [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 38-43.
[5] DING Zichen, WANG Haohua, ZHOU Liwen, CONG Huiwen, LI Chengsheng, BAO Qihan, YANG Yi, WANG Lianyuan, WANG Suzhen, SHI Fuyan. Study on the individualized efficacy for non-small cell lung cancer patients based on Bayesian Additive Regression Tree model [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 92-98.
[6] CHU Zhuxiu, ZHAO Wenjing, LI Xiaoyan, KONG Xiaoli, MA Tingting, JIANG Liyu, YANG Qifeng. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[7] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[8] DENG Xiaohui, GUO Ling. Applications and progress of immunotherapy in repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 32-37.
[9] PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28.
[10] Gang LI,Hao XUE,Wei QIU,Rongrong ZHAO. Research advances in the formation of glioma immunosuppressive microenvironment [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 67-73.
[11] GUO Tian, FU Yilin, GAO Ling, SONG Yongfeng, FU Guobin, GENG Chong, WANG Weibo. Correlation between thyroid hormonal levels and clinical characteristics of 142 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(6): 53-59.
[12] CHEN Rong, LI Haichao, ZHAO Jian. Primary mediastinal seminoma: a case report and literature review [J]. Journal of Shandong University (Health Sciences), 2020, 58(2): 79-84.
[13] ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46.
[14] LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.
[15] WU Depei, CHEN Xiaochen. Current situation and prospect of immunotherapy for lymphoma [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 13-20.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1 -6 .
[2] MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32 -37 .
[3] LONG Tingting, XIE Ming, ZHOU Lu, ZHU Junde. Effect of Noggin protein on learning and memory abilities and the dentate gyrus structure after cerebral ischemia reperfusion injury in mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 15 -23 .
[4] LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38 -46 .
[5] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7 -14 .
[6] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24 -31 .
[7] DING Xiangyun, YU Qingmei, ZHANG Wenfang, ZHUANG Yuan, HAO Jing. Correlation of the expression of insulin-like growth factor II in granulosa cells and ovulation induction outcomes of 84 patients with polycystic ovary syndrome[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 60 -66 .
[8] XU Yuxiang, LIU Yudong, ZHANG Peng, DUAN Ruisheng. A retrospective analysis of risk factors of cerebral microbleeds in 101 patients with cerebral small vessel disease[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 67 -71 .
[9] XIAO Juan, XIAO Qiang, CONG Wei, LI Ting, DING Shouluan, ZHANG Yuan, SHAO Chunchun, WU Mei, LIU Jianing, JIA Hongying. Comparison of diagnostic efficacy of two kinds of thyroid imagine reporting and data systems[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 53 -59 .
[10] GUO Zhihua, ZHAO Daqing, XING Yuan, WANG Wei, LIANG Leping, YANG Jing, ZHAO Qianqian. Single-stage end-to-end anastomosis in the management of severe cervical tracheal stenosis[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 72 -76 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd